Mechanisms of reduced luteal sensitivity to prostaglandin F2alpha during maternal recognition of pregnancy in ewes.
During maternal recognition of pregnancy, the conceptus stimulates endometrial secretion of PGF2alpha and PGE2. However, PGF2alpha is less effective in causing luteal regression in pregnant than in non-pregnant ewes. Experiments were conducted to elucidate mechanisms for reduced luteal sensitivity to PGF2alpha during maternal recognition of pregnancy. Corpora lutea (CL) were collected from pregnant and non-pregnant ewes 0, 4, or 12h following treatment with PGF2alpha on day 12 after estrus. Luteal PTGHS2 mRNA did not differ due to PGF2alpha or pregnancy status. Luteal PTGES mRNA was reduced in both pregnant and non-pregnant ewes after PGF2alpha treatment; while, luteal PTGFS mRNA was reduced 4h after PGF2alpha in pregnant, but not non-pregnant ewes. The result was a greater ratio of PTGES to PTGFS mRNA in pregnant ewes. Luteal mRNA for HPGD did not differ between pregnant and non-pregnant ewes on day 12. Luteal END1 mRNA was reduced in pregnant as compared to non-pregnant ewes prior to PGF2alpha challenge. Luteal END1 mRNA was increased after PGF2alpha in pregnant and non-pregnant ewes; however, ECE1 mRNA was reduced 4h after PGF2alpha in pregnant, but not non-pregnant ewes. The in vitro conversion of PGF2alpha to PGFM was greater in CL of pregnant than non-pregnant ewes at day 14. Luteal conversion of PGF2alpha to PGFM appears to be regulated post-transcriptionally. During maternal recognition of pregnancy, mechanisms of reduced luteal sensitivity to PGF2alpha may include a shift in prostaglandin production to the luteotropin PGE2, a reduction of ECE1 mRNA, and increased catabolism of PGF2alpha.
Costine
Beth A
BA
Division of Animal and Veterinary Sciences, West Virginia University, Morgantown, WV, USA.
Inskeep
E Keith
EK
Blemings
Kenneth P
KP
Flores
Jorge A
JA
Wilson
Matthew E
ME
D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000235:genetics; D003338:Corpus Luteum / Q000737:chemistry / Q000187:drug effects*; D015237:Dinoprost / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000378:metabolism; D019332:Endothelin-1 / Q000235:genetics; D000072396:Endothelin-Converting Enzymes; D005260:Female; D006911:Hydroxyprostaglandin Dehydrogenases / Q000235:genetics; D019746:Intramolecular Oxidoreductases / Q000235:genetics; D003341:Luteolysis / Q000187:drug effects; D008666:Metalloendopeptidases / Q000235:genetics; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D000071876:Prostaglandin-E Synthases; D012333:RNA, Messenger / Q000032:analysis; D012756:Sheep / Q000502:physiology*
D019332:Endothelin-1; D012333:RNA, Messenger; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D015237:Dinoprost; D006911:Hydroxyprostaglandin Dehydrogenases; C031051:prostaglandin-F synthase; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes; D019746:Intramolecular Oxidoreductases; D000071876:Prostaglandin-E Synthases